Status:
COMPLETED
Safety and Pharmacokinetic Characteristics of HD203 Liquid in Healthy Male Volunteers
Lead Sponsor:
Hanwha Chemical
Conditions:
Healthy
Eligibility:
MALE
20-40 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to compare the safety and pharmacokinetic characteristics of HD203 liquid with those of etanercept (enbrel) prefilled injection after subcutaneous injection
Eligibility Criteria
Inclusion
- 20 to 40 years of healthy volunteers
Exclusion
- Subject who had been treated with Etanercept before
Key Trial Info
Start Date :
July 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2015
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT01894412
Start Date
July 1 2013
End Date
December 1 2015
Last Update
July 14 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea